AstraZeneca has revised the efficacy rate for its US Covid-19 vaccine trial down to 76 per cent as the pharmaceutical group sought to address concerns that it had published incomplete interim data earlier this week.
阿斯利康(AstraZeneca)將其美國新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗臨床試驗(yàn)的有效率向下修正為76%。該制藥集團(tuán)尋求化解本周早些時(shí)候出現(xiàn)的、認(rèn)為其發(fā)表了不完整的中期數(shù)據(jù)的擔(dān)憂。
您已閱讀9%（322字），剩余91%（3094字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。